2h agoGuruFocusBULLISH 63Analyst
Why Is KINIKSA PHARMACEUTIC A (KNSA) Stock Moving Today?
By the Top Tier Newswire AI Desk · October 28, 2026 at 12:11 AM ET · reviewed against 21 wire stories
KINIKSA PHARMACEUTIC A (KNSA) is drawing unusual attention today. Our newswire has captured 21 stories on KNSA across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
Kiniksa Pharmaceuticals (KNSA) shares surged 22.23% to close at $89.20. The primary driver was the company’s third-quarter 2026 financial results, which featured a 58% year-over-year increase in ARCALYST revenue and a raised full-year revenue forecast.
What Happened
Kiniksa reported robust third-quarter performance, with ARCALYST sales growing 58% year-over-year. The company raised its 2026 revenue guidance to a range of $1.045 billion to $1.050 billion. Profit growth is outpacing revenue gains, providing the company with resources to advance pipeline candidates without diluting shareholders. The stock closed at a 52-week high, a level it had not previously reached.
Wedbush adjusted its price target on the stock following the release. The company also provided updates on its KPL-387 timeline, with data expected in the second half of 2027. The earnings call presentation highlighted the blockbuster prospects for the Regeneron-partnered drug.
What The Data Shows
The stock printed 19 fresh 52-week highs and two fresh 52-week lows on October 27, 2026. The 52-week range is $35.20 to $84.06, meaning the closing price of $89.20 exceeds the previous high. Over the last eight sessions, the stock moved up 13.5%, rising from $78.59 to $89.20.
Fundamentals show a market cap of $6.0 billion, a P/E ratio of 73.7, and a net margin of 9.6%. Trailing twelve-month revenue grew 58.9%. The stock has a beta of 0.04. In the last 90 days, there were no insider buys and one sale totaling $299,000. Director Cole G Bradley sold shares on July 29, 2026.
What To Watch
Investors will monitor the company’s progress on KPL-387 data, which is expected in the second half of 2027. The stock’s position above its previous 52-week high may draw further attention from analysts and traders.
AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.
KNSA by the numbers
7 sessions: +13.50%Coverage: 21 stories / 8 sourcesAI sentiment: 66/100 (bullish)Mkt cap: $6.0BP/E: 73.752w: $35.20 to $84.06
The headlines behind the move
2h agoGuruFocusBULLISH 63Analyst
KNSA Maintained by Wells Fargo -- Price Target Raised to $110
6h agoThe FlyBULLISH 64Analyst
Kiniksa price target raised to $101 from $90 at Goldman Sachs
7h agoInvesting.com Analyst RatingsBULLISH 64Analyst
Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales
Goldman Sachs raises Kiniksa stock price target on strong Arcalyst sales
22h agoSeeking AlphaNEUTRAL 50Earnings
Kiniksa Pharmaceuticals International, plc 2026 Q3 - Results - Earnings Call Presentation
2026-10-27. The following slide deck was published by Kiniksa Pharmaceuticals International, plc in conjunction with their 2026 Q3 earnings call.
23h agoThe Motley FoolBULLISH 63General
Kiniksa Pharmaceuticals: 3 Key Takeaways for Long-Term Investors
Profit growth is outpacing revenue gains, giving the company firepower to advance pipeline candidates without diluting shareholders.
1d agoThe Motley FoolBULLISH 74Earnings
Kiniksa (KNSA) Q3 2026 Earnings Call Transcript
ARCALYST revenue surged 58% year-over-year as the company raised full-year guidance.
1d agoThe FlyBULLISH 74General
Kiniksa rises 20.4%
1d agoGuruFocusBULLISH 78Earnings
Kiniksa Pharmaceuticals (KNSA) Shares Surge to 52-Week High on Robust Q3 Earnings
1d agoGuruFocusBULLISH 67Earnings
Kiniksa Pharmaceuticals Raises 2026 Revenue Forecast Amid Strong ARCALYST Sales (KNSA)
Frequently asked questions
Why is KNSA stock moving today?
KINIKSA PHARMACEUTIC A (KNSA) is drawing unusual attention today. Our newswire has captured 21 stories on KNSA across 8 sources in the last 36 hours, with AI sentiment reading bullish (avg 66/100). The most recent driver: "KNSA Maintained by Wedbush -- Price Target Raised to $102" (GuruFocus).
Is KNSA a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of KNSA coverage reads 66/100 over 21 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is GMAB up today (+28.95%)
- Why is AXGN up today (+28.91%)
- Why is FFIV down today (-20.48%)
- Why is SLS down today (-18.36%)
- Why is ENPH down today (-16.70%)
- Why is RAPP down today (-16.30%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on KNSA: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.
Earlier KNSA move explainers: 2026-10-28 · 2026-07-28